A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
T cell immunity directed against tumor-encoded amino acid substitutions occurs in some melanoma patients. This implicates missense mutations as a source of patient-specific neoantigens. However, a systematic evaluation of these putative neoantigens as targets of antitumor immunity is lacking. Moreover, it remains unknown whether vaccination can augment such responses. We found that a dendritic cell vaccine led to an increase in naturally occurring neoantigen-specific immunity and revealed previously undetected human leukocyte antigen (HLA) class I-restricted neoantigens in patients with advanced melanoma. The presentation of neoantigens by HLA-A*02:01 in human melanoma was confirmed by mass spectrometry. Vaccination promoted a diverse neoantigen-specific T cell receptor (TCR) repertoire in terms of both TCR-β usage and clonal composition. Our results demonstrate that vaccination directed at tumor-encoded amino acid substitutions broadens the antigenic breadth and clonal diversity of antitumor immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Vaccines have been used as an approach to enhance anti-tumor immune responses and have demonstrated encouraging results in preclinical and clinical studies, leading to an expansion of the intratumoral T cell infiltration and anti-tumor immune responses (Carreno et al., 2015; Ott et al., 2017).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Carreno et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Flicek, P., Amode, M. R., Barrell, D., Beal, K., Billis, K., Brent, S., Carvalho-Silva, D., Clapham, P., Coates, G., Fitzgerald, S., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1196 · Cited by 1,214
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
Coulie, P. G., Van den Eynde, B. J., van der Bruggen, P., & Boon, T. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3670 · Cited by 1,138
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,111
Reliable prediction of T‐cell epitopes using neural networks with novel sequence representations
Nielsen, M., Lundegaard, C., Worning, P., Lauemøller, S. L., Lamberth, K., Buus, S., Brunak, S., & Lund, O. (2003) · Protein Science · doi:10.1110/ps.0239403 · Cited by 1,074
Robbins, P. F., Lu, Y.-C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., Lin, J. C., Teer, J. K., Cliften, P., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,072
Cited by
Items 201–300 of 1,003
Personalized neoantigen vaccines: A new approach to cancer immunotherapy
Aldous, A. R., & Dong, J. Z. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.10.021 · Cited by 128
Gainor, J. F., Patel, M. R., Weber, J. S., Gutierrez, M., Bauman, J. E., Clarke, J. M., Julian, R., Scott, A. J., Geiger, J. L., Kirtane, K., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0158 · Cited by 124
Roufas, C., Chasiotis, D., Makris, A., Efstathiades, C., Dimopoulos, C., & Zaravinos, A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00027 · Cited by 125
Novel approaches for the design, delivery and administration of vaccine technologies
Wallis, J., Shenton, D. P., & Carlisle, R. C. (2019) · Clinical and Experimental Immunology · doi:10.1111/cei.13287 · Cited by 123
Neoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response
Mardis, E. R. (2019) · Genome Medicine · doi:10.1186/s13073-019-0684-0 · Cited by 123
Self-citationNanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy
Fang, R. H., Kroll, A. V., & Zhang, L. (2015) · Small · doi:10.1002/smll.201501284 · Cited by 123
Fehlings, M., Simoni, Y., Penny, H. L., Becht, E., Loh, C. Y., Gubin, M. M., Ward, J. P., Wong, S. C., Schreiber, R. D., & Newell, E. W. (2017) · Nature Communications · doi:10.1038/s41467-017-00627-z · Cited by 115
Computational Prediction and Validation of Tumor-Associated Neoantigens
Roudko, V., Greenbaum, B., & Bhardwaj, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00027 · Cited by 122
Ex vivo pulsed dendritic cell vaccination against cancer
Gu, Y., Zhao, X., & Song, X. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0415-5 · Cited by 122
Targeting KRAS in pancreatic cancer: new drugs on the horizon
Bannoura, S. F., Uddin, M. H., Nagasaka, M., Fazili, F., Hallak, M. N. A., Philip, P. A., El‐Rayes, B. F., & Azmi, A. S. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09990-2 · Cited by 122
Past, Current, and Future of Immunotherapies for Prostate Cancer
Boettcher, A. N., Usman, A., Morgans, A., VanderWeele, D. J., Sosman, J. A., & Wu, J. D. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00884 · Cited by 122
Biomimetic Nano-Drug Delivery System: An Emerging Platform for Promoting Tumor Treatment
Han, X., Gong, C., Yang, Q., Zheng, K., Wang, Z., & Zhang, W. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s442877 · Cited by 121
Induction of neoantigen-reactive T cells from healthy donors
Ali, M., Földvári, Z., Giannakopoulou, E., Böschen, M.-L., Strønen, E., Yang, W., Toebes, M., Schubert, B., Kohlbacher, O., Schumacher, T. N., et al. (2019) · Nature Protocols · doi:10.1038/s41596-019-0170-6 · Cited by 119
Mukherjee, S., Mukherjee, S., Abourehab, M. A. S., Sahebkar, A., & Kesharwani, P. (2022) · European Polymer Journal · doi:10.1016/j.eurpolymj.2022.111471 · Cited by 118
Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations
Lee, K.-W., Yam, J. W. P., & Mao, X. (2023) · Cells · doi:10.3390/cells12172147 · Cited by 117
Trial watch: Dendritic cell-based anticancer immunotherapy
Garg, A. D., Vara Perez, M., Schaaf, M., Agostinis, P., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1328341 · Cited by 117
Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry
Freudenmann, L. K., Marcu, A., & Stevanović, S. (2018) · Immunology · doi:10.1111/imm.12936 · Cited by 109
Calmeiro, J., Carrascal, M. A., Tavares, A. R., Ferreira, D. A., Gomes, C. M. F., Falcão, A. C., Cruz, M. T., & Neves, B. M. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020158 · Cited by 116
Tumour-wide RNA splicing aberrations generate actionable public neoantigens
Kwok, D. W., Stevers, N. O., Etxeberría, I., Nejo, T., Cove, M. C., Chen, L. H., Jung, J., Okada, K., Lakshmanachetty, S., Gallus, M., et al. (2025) · Nature · doi:10.1038/s41586-024-08552-0 · Cited by 116
Johanns, T. M., Ward, J. P., Miller, C. A., Wilson, C., Kobayashi, D. K., Bender, D. E., Fu, Y., Alexandrov, A., Mardis, E. R., Artyomov, M. N., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0156 · Cited by 116
Self-citationQin, L., Zhang, H., Zhou, Y., Umeshappa, C. S., & Gao, H. (2021) · Small · doi:10.1002/smll.202006000 · Cited by 115
Sensitive identification of neoantigens and cognate TCRs in human solid tumors
Arnaud, M., Chiffelle, J., Genolet, R., Rodrigo, B. N., Perez, M. A. S., Huber, F., Magnin, M., Nguyen‐Ngoc, T., Guillaume, P., Baumgaertner, P., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-021-01072-6 · Cited by 115
Okoye, I., Houghton, M., Tyrrell, D. L., Barakat, K., & Elahi, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01215 · Cited by 116
Lin, H., Yang, C., Luo, Y., Ge, M., Shen, H., Zhang, X., & Shi, J. (2022) · ACS Nano · doi:10.1021/acsnano.1c11132 · Cited by 114
Impaired function of dendritic cells within the tumor microenvironment
Xiao, Z., Wang, R., Wang, X., Yang, H., Dong, J.-M., He, X., Yang, Y., Guo, J., Cui, J., & Zhou, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1213629 · Cited by 114
Bear, A. S., Blanchard, T., Cesare, J., Ford, M. J., Richman, L. P., Xu, C., Baroja, M. L., McCuaig, S., Costeas, C., Gabunia, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24562-2 · Cited by 113
Self-citationINTEGRATE-neo: a pipeline for personalized gene fusion neoantigen discovery
Zhang, J., Mardis, E. R., & Maher, C. A. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btw674 · Cited by 113
Self-citationMonitoring immune responses in the tumor microenvironment
Wargo, J. A., Reddy, S. M., Reuben, A., & Sharma, P. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.05.006 · Cited by 113
Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy
Sultan, H., Takeuchi, Y., Ward, J. P., Sharma, N., Liu, T., Sukhov, V., Firulyova, M. M., Song, Y., Ameh, S., Brioschi, S., et al. (2024) · Nature · doi:10.1038/s41586-024-07752-y · Cited by 113
Advances in personalized cancer immunotherapy
Kakimi, K., Karasaki, T., Matsushita, H., & Sugie, T. (2016) · Breast Cancer · doi:10.1007/s12282-016-0688-1 · Cited by 114
Mutation position is an important determinant for predicting cancer neoantigens
Capietto, A.-H., Jhunjhunwala, S., Pollock, S. B., Lupardus, P. J., Wong, J., Hänsch, L., Cevallos, J., Chestnut, Y., Fernandez, A., Lounsbury, N., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20190179 · Cited by 110
Dillman, R. O., Cornforth, A. N., Nistor, G. I., McClay, E. F., AMATRUDA, T. T., & DePriest, C. B. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0330-1 · Cited by 109
A second chance for telomerase reverse transcriptase in anticancer immunotherapy
Zanetti, M. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.67 · Cited by 109
Duperret, E. K., Perales-Puchalt, A., Stoltz, R., G.H., H., Mandloi, N., Barlow, J., Chaudhuri, A., Sardesai, N. Y., & Weiner, D. B. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0283 · Cited by 108
Dendritic Cells and Immunogenic Cancer Cell Death: A Combination for Improving Antitumor Immunity
Lamberti, M. J., Nigro, A., Mentucci, F. M., Vittar, N. B. R., Casolaro, V., & Col, J. D. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030256 · Cited by 109
Erfani, A., Diaz, A. E., & Doyle, P. S. (2023) · Materials Today · doi:10.1016/j.mattod.2023.03.006 · Cited by 108
Vici, P., Pizzuti, L., Mariani, L., Zampa, G., Santini, D., Lauro, L. D., Gamucci, T., Natoli, C., Marchetti, P., Barba, M., et al. (2016) · Expert Review of Vaccines · doi:10.1080/14760584.2016.1176533 · Cited by 107
Therapeutic cancer vaccines: From initial findings to prospects
Song, Q., Zhang, C.-D., & Wu, X.-H. (2018) · Immunology Letters · doi:10.1016/j.imlet.2018.01.011 · Cited by 106
“A study showed that the next-generation DC vaccine loaded with a neoantigen can increase neoantigen-specific T lymphocytes [69].”
BackgroundChen, X., Yang, J., Wang, L., & Liu, B. (2020) · Theranostics · doi:10.7150/thno.38742 · Cited by 106
Immunotherapy of cancers comes of age
Yousefi, H., Yuan, J. D., Keshavarz‐Fathi, M., Murphy, J. F., & Rezaei, N. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1366315 · Cited by 106
Hu, Y., Wang, Z., Hu, H., Wan, F., Chen, L., Xiong, Y., Wang, X., Zhao, D., Huang, W., & Zeng, J. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz427 · Cited by 105
Cimen Bozkus, C., Roudko, V., Finnigan, J. P., Mascarenhas, J., Hoffman, R., Iancu-Rubin, C., & Bhardwaj, N. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1356 · Cited by 105
Promising approaches in cancer immunotherapy
Taefehshokr, N., Baradaran, B., Baghbanzadeh, A., & Taefehshokr, S. (2019) · Immunobiology · doi:10.1016/j.imbio.2019.11.010 · Cited by 105
Li, J., Xiao, Z., Wang, D., Jia, L., Nie, S., Zeng, X., & Hu, W. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01844-5 · Cited by 105
The Cellular Immunotherapy Revolution: Arming the Immune System for Precision Therapy
Paucek, R. D., Baltimore, D., & Li, G. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.002 · Cited by 104
Neoantigen Targeting—Dawn of a New Era in Cancer Immunotherapy?
Wirth, T. C., & Kühnel, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01848 · Cited by 98
Esprit, A., de Mey, W., Bahadur Shahi, R., Thielemans, K., Franceschini, L., & Breckpot, K. (2020) · Vaccines · doi:10.3390/vaccines8040776 · Cited by 103
An Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors
Lu, Y.-C., Zheng, Z., Robbins, P. F., Tran, E., Prickett, T. D., Gartner, J. J., Li, Y. F., Ray, S., Franco, Z., Bliskovsky, V., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.018 · Cited by 103
Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy
Sánchez-Paulete, A. R., Teijeira, Á., Cueto, F. J., Garasa, S., Perez‐Gracia, J. L., Sánchez-Arráez, Á., Sancho, D., & Melero, I. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx727 · Cited by 103
Breast Cancer Neoantigens Can Induce CD8+ T-Cell Responses and Antitumor Immunity
Zhang, X., Kim, S., Hundal, J., Herndon, J. M., Li, S., Petti, A. A., Soysal, S. D., Li, L., McLellan, M. D., Hoog, J., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0264 · Cited by 102
Self-citationSystems Immunology: Learning the Rules of the Immune System
Villani, A., Sarkizova, S., & Hacohen, N. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053035 · Cited by 102
Engineering Precision Medicine
Sun, W., Lee, J., Zhang, S., Benyshek, C., Dokmeci, M. R., & Khademhosseini, A. (2018) · Advanced Science · doi:10.1002/advs.201801039 · Cited by 103
D’Alise, A. M., Leoni, G., Cotugno, G., Troise, F., Langone, F., Fichera, I., Lucia, M. D., Avalle, L., Vitale, R. L., Leuzzi, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10594-2 · Cited by 102
Characteristics of TCR Repertoire Associated With Successful Immune Checkpoint Therapy Responses
Kidman, J., Principe, N., Watson, M. W., Lassmann, T., Holt, R. A., Nowak, A. K., Lesterhuis, W. J., Lake, R., & Chee, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.587014 · Cited by 102
Melssen, M. M., Petroni, G. R., Chianese-Bullock, K. A., Wages, N. A., Grosh, W. W., Varhegyi, N., Smolkin, M. E., Smith, K. T., Galeassi, N. V., Deacon, D. H., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0625-x · Cited by 101
The neoepitope landscape of breast cancer: implications for immunotherapy
Narang, P., Chen, M., Sharma, A. A., Anderson, K. S., & Wilson, M. A. (2019) · BMC Cancer · doi:10.1186/s12885-019-5402-1 · Cited by 101
Wood, M. A., Weeder, B. R., David, J. K., Nellore, A., & Thompson, R. F. (2020) · Genome Medicine · doi:10.1186/s13073-020-00729-2 · Cited by 99
Bonté, P.-E., Arribas, Y. A., Merlotti, A., Carrascal, M., Zhang, J. V., Zueva, E., Binder, Z. A., Alanio, C., Goudot, C., & Amigorena, S. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110916 · Cited by 74
Dysfunction of dendritic cells in tumor microenvironment and immunotherapy
Chen, J., Duan, Y.-H., Che, J., & Zhu, J. (2024) · 癌症:英文版 · doi:10.1002/cac2.12596 · Cited by 99
The Human Immunopeptidome Project: A Roadmap to Predict and Treat Immune Diseases
Vizcaíno, J. A., Kubiniok, P., Kovalchik, K. A., Ma, Q., Duquette, J. D., Mongrain, I., Deutsch, E. W., Peters, B., Sette, A., Sirois, I., et al. (2020) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r119.001743 · Cited by 99
Predicting T cell recognition of MHC class I restricted neoepitopes
Koşaloğlu‐Yalçın, Z., Lanka, M., Frentzen, A., Premlal, A. L. R., Sidney, J., Vaughan, K. C., Greenbaum, J., Robbins, P. F., Gartner, J. J., Sette, A., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1492508 · Cited by 98
Zhang, X., Goedegebuure, S. P., Chen, M. Y., Mishra, R., Zhang, F., Yu, Y. Y., Singhal, K., Li, L., Gao, F., Myers, N. B., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01388-3 · Cited by 98
Self-citationpTuneos: prioritizing tumor neoantigens from next-generation sequencing data
Zhou, C., Wei, Z., Zhang, Z., Zhang, B., Zhu, C., Chen, K., Chuai, G., Qu, S., Xie, L., Gao, Y., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0679-x · Cited by 97
Cancer Vaccines: Antigen Selection Strategy
Zhao, Y., Baldin, A. V., Isayev, O., Werner, J., Zamyatnin, A. A., & Bazhin, A. V. (2021) · Vaccines · doi:10.3390/vaccines9020085 · Cited by 98
Tumor Immunity and Survival as a Function of Alternative Neopeptides in Human Cancer
Rech, A. J., Balli, D., Mantero, A., Ishwaran, H., Nathanson, K. L., Stanger, B. Z., & Vonderheide, R. H. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0559 · Cited by 94
The perfect personalized cancer therapy: cancer vaccines against neoantigens
Aurisicchio, L., Pallocca, M., Ciliberto, G., & Palombo, F. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0751-1 · Cited by 97
Vaccines for immunoprevention of cancer
Enokida, T., Moreira, A., & Bhardwaj, N. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146956 · Cited by 96
Development of therapeutic vaccines for the treatment of diseases
Tian, Y., Hu, D., Li, Y., & Li, Y. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00098-9 · Cited by 96
Opportunities for immunotherapy in microsatellite instable colorectal cancer
Westdorp, H., Fennemann, F. L., Weren, R. D. A., Bisseling, T. M., Ligtenberg, M. J. L., Figdor, C. G., Schreibelt, G., Hoogerbrugge, N., Wimmers, F., & de Vries, I. J. M. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1832-7 · Cited by 96
Innovative Immunization Strategies for Antivenom Development
Bermúdez-Méndez, E., Fuglsang-Madsen, A., Føns, S., Lomonte, B., Gutiérrez, J. M., & Laustsen, A. H. (2018) · Toxins · doi:10.3390/toxins10110452 · Cited by 95
Chen, H., Li, Z., Qiu, L., Dong, X., Chen, G., Shi, Y., Cai, L., Liu, W., Ye, H., Zhou, Y., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004389 · Cited by 95
Biomaterials Facilitating Dendritic Cell‐Mediated Cancer Immunotherapy
Dong, H., Li, Q., Zhang, Y., Ding, M., Teng, Z., & Mou, Y. (2023) · Advanced Science · doi:10.1002/advs.202301339 · Cited by 95
Wang, D., Cui, Q., Yang, Y. J., Liu, A. Q., Zhang, G., & Yu, J. C. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113541 · Cited by 94
Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer
Liu, D., Che, X., Wang, X., Ma, C., & Wu, G. (2023) · Pharmaceuticals · doi:10.3390/ph16101384 · Cited by 94
Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and Validation
Borden, E. S., Buetow, K. H., Wilson, M. A., & Hastings, K. T. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.836821 · Cited by 78
Harnessing Tumor Mutations for Truly Individualized Cancer Vaccines
Vormehr, M., Türeci, Ö., & Sahin, U. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-042617-101816 · Cited by 92
Guo, Z., Yuan, Y., Chen, C., Lin, J., Ma, Q., Liu, G., Gao, Y. L., Huang, Y., Chen, L., Chen, L., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00279-3 · Cited by 92
Engelhard, V. H., Obeng, R. C., Cummings, K. L., Petroni, G. R., Ambakhutwala, A. L., Chianese-Bullock, K. A., Smith, K. T., Lulu, A., Varhegyi, N., Smolkin, M. E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000262 · Cited by 85
Filley, A. C., Henriquez, M., & Dey, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00453 · Cited by 91
Personalized T cell-mediated cancer immunotherapy: progress and challenges
Bethune, M. T., & Joglekar, A. V. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.03.024 · Cited by 91
Liu, C. J., Schaettler, M. O., Blaha, D. T., Bowman-Kirigin, J. A., Kobayashi, D. K., Livingstone, A. J., Bender, D. E., Miller, C. A., Kranz, D. M., Johanns, T. M., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa050 · Cited by 90
Pak, H., Michaux, J., Huber, F., Chong, C., Stevenson, B. J., Müller, M., Coukos, G., & Bassani‐Sternberg, M. (2021) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2021.100080 · Cited by 90
Designing neoantigen cancer vaccines, trials, and outcomes
Biswas, N., Chakrabarti, S., Padul, V. G., Jones, L. D., & Ashili, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1105420 · Cited by 90
Chen, Y., Zhi, S., Ou, J., Gao, J., Zheng, L., Huang, M., Du, S., Shi, L., Tu, Y., & Cheng, K. (2023) · ACS Nano · doi:10.1021/acsnano.3c02724 · Cited by 90
Müller, M., Gfeller, D., Coukos, G., & Bassani-Sternberg, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01367 · Cited by 90
Therapeutic cancer vaccine: building the future from lessons of the past
Tran, T., Blanc, C., Granier, C., Saldmann, A., Tanchot, C., & Tartour, É. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0691-z · Cited by 89
Millar, D. G., Ramjiawan, R. R., Kawaguchi, K., Gupta, N., Jiang, C., Zhang, S., Nojiri, T., Ho, W. W., Aoki, S., Jung, K., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-019-0404-8 · Cited by 89
Matsushita, H., Sato, Y., Karasaki, T., Nakagawa, T., Kume, H., Ogawa, S., Homma, Y., & Kakimi, K. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0225 · Cited by 87
Therapeutic strategies to remodel immunologically cold tumors
Wang, M., Wang, S., Desai, J., Trapani, J. A., & Neeson, P. J. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1226 · Cited by 88
The current clinical landscape of personalized cancer vaccines
Fritah, H., Rovelli, R., Chiang, C. L.-L., & Kandalaft, L. E. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102383 · Cited by 86
Circadian clock: a regulator of the immunity in cancer
Zhang, Z., Zeng, P., Gao, W., Zhou, Q., Feng, T., & Tian, X. (2021) · Cell Communication and Signaling · doi:10.1186/s12964-021-00721-2 · Cited by 86
Cancer vaccines: past, present and future; a review article
Grimmett, E., Al-Share, B. A., Alkassab, M. B., Zhou, R. W., Desai, A., Rahim, M. M. A., & Woldie, I. (2022) · Discover Oncology · doi:10.1007/s12672-022-00491-4 · Cited by 86
mRNA: A promising platform for cancer immunotherapy
Kong, B., Kim, Y., Kim, E. H., Suk, J. S., & Yang, Y. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114993 · Cited by 88
Antigen cross-presentation by dendritic cells: A critical axis in cancer immunotherapy
Moussion, C., & Delamarre, L. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101848 · Cited by 87
Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer
Liu, S., Matsuzaki, J., Wei, L., Tsuji, T., Battaglia, S., Hu, Q., Cortes, E., Wong, L., Yan, L., Long, M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0629-6 · Cited by 85
PSSMHCpan: a novel PSSM-based software for predicting class I peptide-HLA binding affinity
Liu, G., Li, D., Li, Z., Qiu, S., Li, W., Chao, C., Yang, N., Li, H., Cheng, Z., Song, X., et al. (2017) · GigaScience · doi:10.1093/gigascience/gix017 · Cited by 85
Molecular Frontiers in Melanoma: Pathogenesis, Diagnosis, and Therapeutic Advances
Kim, H. J., & Kim, Y. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052984 · Cited by 84
Sensitive Detection and Analysis of Neoantigen-Specific T Cell Populations from Tumors and Blood
Peng, S., Zaretsky, J. M., Ng, A. H. C., Chour, W., Bethune, M. T., Choi, J., Hsu, A., Holman, E., Ding, X., Guo, K., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.106 · Cited by 83
A covalent organic framework as a nanocarrier for synergistic phototherapy and immunotherapy
Zhou, Y., Liu, S., Hu, C., Cai, L., & Pang, M. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb00679c · Cited by 82
Peng, S., Chen, S., Hu, W., Mei, J., Zeng, X., Su, T., Wang, W., Chen, Z., Xiao, H., Zhou, Q., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0931 · Cited by 82
Metadata
- Authors
- Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., & Linette, G. P.
- Affiliations
- Washington University in St. Louis (US)
- Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
- University of Oklahoma Health Sciences Center (US)
- MilliporeSigma (United States) (US)
- Corresponding author
- Carreno, Beatriz M.
- ORCID
- Venue
- Science
- Published
- 2015-05-15
- Volume
- 348
- Issue
- 6236
- Pages
- 803-808
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4549796
- OpenAlex
- W2007026865
- Cited by
- 1,285
- References
- 37
- Citations by year
- 2026: 45 · 2025: 90 · 2024: 104 · 2023: 108 · 2022: 126 · 2021: 159 · 2020: 135 · 2019: 138 · 2018: 124 · 2017: 118 · 2016: 99 · 2015: 38
- FWCI
- 62.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Human Genome Research Institute (5U54HG00307)
- National Cancer Institute (P30 CA91842, R21 CA179695)
- Barnes-Jewish Hospital Foundation
- Siteman Cancer Frontier Fund
- Our Mark on Melanoma (MOM) Foundation
- Come Out Swinging (COS) Foundation
- Blackout Melanoma Foundation
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- dendritic cell vaccine, melanoma, neoantigens, missense mutations, T cell receptor repertoire, HLA-A*0201, T cell-mediated antitumor immunity, clonal diversity, cancer immunotherapy
- MeSH terms
- Antigens, Neoplasm, Dendritic Cells, Humans, Melanoma, Mutation, Skin Neoplasms, T-Lymphocytes, Monitoring, Immunologic, HLA-A2 Antigen, Immunotherapy, Active, Receptors, Antigen, T-Cell, alpha-beta, Antigen Presentation, Cancer Vaccines, Amino Acid Substitution
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.